In vitro and in vivo characterization of A-940894: A potent histamine H 4 receptor antagonist with anti-inflammatory properties

British Journal of Pharmacology

Volumn 157, Issue 1, 2009, Pages 44-54

  Strakhova, M I ^a   Cuff, C A ^a   Manelli, A M ^a   Carr, T L ^a   Witte, D G ^a   Baranowski, J L ^a   Vortherms, T A ^a   Miller, T R ^a   Rundell, L ^a   McPherson, M J ^a   Adair, R M ^a   Brito, A A ^a   Bettencourt, B M ^a   Yao, B B ^a   Wetter, J M ^a   Marsh, K C ^a   Liu, H ^a   Cowart, M D ^a   Brioni, J D ^a   Esbenshade, T A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

A 940894; Chemotaxis; Eosinophils; Histamine; h 4; Mast cells; Receptor binding; Selective antagonist; Shape change; Zymosan

Indexed keywords

4 PIPERAZIN 1 YL 6,7 DIHYDRO 5H BENZO[6,7]CYCLOHEPTA[1,2 D]PYRIMIDIN 2 YLAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE H3 RECEPTOR; HISTAMINE H4 RECEPTOR ANTAGONIST; PROSTAGLANDIN D2; UNCLASSIFIED DRUG; ZYMOSAN; 4 PIPERAZIN 1 YL 6,7 DIHYDRO 5H BENZO(6,7)CYCLOHEPTA(1,2 D)PYRIMIDIN 2 YLAMINE; 4-PIPERAZIN-1-YL-6,7-DIHYDRO-5H-BENZO(6,7)CYCLOHEPTA(1,2-D)PYRIMIDIN-2-YLAMINE; CALCIUM; G PROTEIN COUPLED RECEPTOR; HISTAMINE; HISTAMINE RECEPTOR; HRH4 PROTEIN, HUMAN; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCIUM MOBILIZATION; CELL SHAPE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG STRUCTURE; EOSINOPHIL; FEMALE; FLUOROMETRY; HUMAN; MALE; MAST CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERITONITIS; PRIORITY JOURNAL; RADIOASSAY; RAT; ANIMAL; BAGG ALBINO MOUSE; BINDING COMPETITION; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; CHEMOTAXIS; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING, COMPETITIVE; CALCIUM; CELL SHAPE; CHEMOTAXIS; EOSINOPHILS; FEMALE; HISTAMINE; HUMANS; MALE; MAST CELLS; MICE; MICE, INBRED BALB C; PERITONITIS; PIPERAZINES; PROSTAGLANDIN D2; PYRIMIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE; RECOMBINANT PROTEINS; RNA, MESSENGER; ZYMOSAN;

EID: 67149138452     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00236.x     Document Type: Article

References (36)

1. Ajuebor MN, Flower RJ, Hannon R, Christie M, Bowers K, Verity A et al. (1998). Endogenous monocyte chemoattractant protein-1 recruits monocytes in the zymosan peritonitis model. J Leukoc Biol 63: 108-116. (Pubitemid 28070389)
2. 4 Receptor ligands. J Med Chem 51: 6547-6557.
3. Ajuebor MN, Das AM, Virag L, Flower RJ, Szabo C, Perretti M (1999). Role of resident peritoneal macrophages and mast cells in chemokine production and neutrophil migration in acute inflammation: evidence for an inhibitory loop involving endogenous IL-10. J Immunol 162: 1685-1691. (Pubitemid 29307046)
4. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2): S1-S209.
5. Bradley PP, Priebat DA, Christensen RD, Rothstein G (1982). Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78: 206-209.
6. 4 receptor. Br J Pharmacol 140: 1117-1127.
7. Cheng Y, Prusoff WH (1973). Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (ISO) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
8. Coruzzi G, Adami M, Guaita E, de Esch IJ, Leurs R (2007). Antiinflammatory and antinociceptive effects of the selective histamine H4-receptor antagonists JNJ7777120 and VUF6002 in a rat model of carrageenan-lnduced acute inflammation. Eur J Pharmacol 563: 240-244. (Pubitemid 46602245)
9. Cowart MD, Altenbach RJ, Liu H, Hsieh GC, Drizin I, Milicic I et al. (2008). Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. J Med Chem 51: 6571-6580.
10. Damaj BB, Becerra CB, Esber HJ, Wen Y, Maghazachi AA (2007). Functional expression of H4 histamine receptor in human natural killer cells, monocytes, and dendritic cells. J Immunol 179: 907-7915.
11. Daugherty BL (2004). Histamine H4 antagonism: a therapy for chronic allergy? Br J Pharmacol 142: 5-7.
12. Doherty NS, Poubelle P, Borgeat P, Beaver TH, Westrich GL, Schrader NL (1985). Intraperitoneal injection of zymosan in mice induces pain, inflammation and the synthesis of peptidoleukotrienes and prostaglandin E2. Prostaglandins 30: 769-789. (Pubitemid 16199279)
13. Dunford PJ, O'Donnell N, Riley JP, Williams KN, Karlsson L, Thurmond RL (2006). The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. J Immunol 176: 7062-7070. (Pubitemid 43787887)
14. Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG et al. (2003). Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920:1. In vitro pharmacological effects. J Pharmacol Exp Ther 305: 887-896. (Pubitemid 36617965)
15. Fokkens WJ, Godthelp T, Holm AF, Blom H, Mulder PG, Vroom TM et al. (1992). Dynamics of mast cells in the nasal mucosa of patients with allergic rhinitis and non-allergic controls: a biopsy study. Clin Exp Allergy 22: 701-710.
16. Fung-Leung W-P, Thurmond RL, Ling P, Karlsson L (2004). Histamine H4 receptor antagonists: the new antihistamines? Curr Opin Investig Drugs 5: 1174-1183. (Pubitemid 39545286)
17. Godot V, Arock M, Garcia G, Capel F, Flys C, Dy M et al. (2007). H4 histamine receptor mediates optimal migration of mast cell precursors to CXCL12. J Allergy Clin Immunol 120: 827-834. (Pubitemid 47531837)
18. Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung W-P (2003). Histamine H4 receptor mediates Chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Titer 305: 1212-1221.
19. Jablonowski JA, Grice CA, Chai W, Dvorak CA, Venable JD, Kwok AK et al. (2003). The first potent and selective non-imidazole human histamine H4 receptor antagonists. J Med Chem 46: 3957-3960. (Pubitemid 37122442)
20. Kolaczkowska E, Seljelid R, Plytycz B (2001a). Role of mast cells in zymosan-induced peritoneal inflammation in Balb/c and mast celldeficient WBB6F1 mice. J Leukoc Biol 69: 33-42. (Pubitemid 32095114)
21. Kolaczkowska E, Seljelid R, Plytycz B (2001b). Critical role of mast cells in morphine-mediated impairment of zymosan-induced peritonitis in mice. Inflamm Res 50: 415-421. (Pubitemid 32777668)
22. Leff P, Dougall IG (1993). Further concerns over Cheng-Prusoff analysis. Trends Pharmacol Sci 14: 110-112.
23. Ling P, Ngo K, Nguyen S, Thurmond RL, Edwards JP, Karlsson L et al. (2004). Histamine H4 receptor mediates eosinophil Chemotaxis with cell shape change and adhesion molecule upregulation. Br J Pharmacol 142: 161-171. (Pubitemid 38698205)
24. Liu C, Ma X, Jiang X, Wilson SJ, Hofstra CL, Blevitt J et al. (2001a). Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol 59: 420-426. (Pubitemid 32179918)
25. Liu C, Wilson SJ, Kuei C, Lovenberg TW (2001b). Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J Pharmacol Exp Ther 299: 121-130. (Pubitemid 32905126)
26. Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LGR et al. (2008). cis-4-(piperazin-l-yl)-5,6,7a,8,9,10,11,11aoctahydrobenzofuro[2,3-h] quinazolin-2-amine (A-987306), a new histamine H4 antagonist that blocks pain responses against carrageenan-induced hyperalgesia. J Med Chem 51: 7094-7098.
27. Morse KL, Behan J, Laz TM, West RE, Greenfeder SA, Anthes JC et al. (2001). Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther 296: 1058-1066. (Pubitemid 32187382)
28. Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S (2000). Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed In leukocytes. J Biol Chem 275: 36781-36786. (Pubitemid 32002087)
29. Slater A, Smallman LA, Drake-Lee AB (1996). Increase in epithelial mast cell numbers in the nasal mucosa of patients with perennial allergic rhinitis. J Laryngol Otol 110: 929-933. (Pubitemid 26355862)
30. Strakhova M, Esbenshade TA (2006). Characterization of histaminergic receptors. In: Enna SJ (ed.). Current Protocols in Pharmacology. John Wiley and Sons: New Jersey, pp. 1.19.11-11.19.23.
31. Takeshita K, Bacon KB, Gantner F (2004). Critical role of L-selectin and histamine H4 receptor in zymosan-induced neutrophil recruitment from the bone marrow: comparison with carrageenan. J Pharmacol Exp Ther 310: 272-280. (Pubitemid 38812721)
32. Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung W-P, Hofstra CL, Jiang W et al. (2004). A potent and selective histamine H4 receptor antagonist with anti- inflammatory properties. J Pharmacol Exp Ther 309: 404-413. (Pubitemid 38393154)
33. Thurmond RL, Gelfand EW, Dunford PJ (2008). The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 7: 41-53.
34. Varga C, Horvath K, Berko A, Thurmond RL, Dunford PJ, Whittle BJ (2005). Inhibitory effects of histamine H4 receptor antagonists on experimental colitis in the rat. Eur J Pharmacol 522: 130-138. (Pubitemid 41456659)
35. Yao BB, Sharma R, Cassar S, Esbenshade TA, Hancock AA (2003). Cloning and pharmacological characterization of the monkey histamine H3 receptor. Eur J Pharmacol 482: 49-60. (Pubitemid 37505926)
36. Zhang M, Venable JD, Thurmond RL (2006). The histamine H4 receptor in autoimmune disease. Expert Opin Investig Drugs 15: 1443-1452.